Abstract
Background. Pancreatic intraductal papillary mucinous neoplasms (IPMN), morphologically resembling colonic adenomas, often have an indefinable malignant potential. We used a monoclonal antibody (MAb) raised against colonic adenomas, Adnab-9, to identify patients with a better prognosis. Methods. We assessed Adnab-9-labeled sections of these neoplasms from 50 patients, 13 pancreatic adenocarcinomas, and 32 colonic adenomas using standard immunohistochemical techniques. Results. 26% of the IPMNs labeled with Adnab-9 as compared to 0% of pancreatic ductal cancers or surrounding benign tissues, (p <0.001) and 53% of adenomas (p <0.025). Labeling in IPMNs was usually seen in the noninvasive epithelium suggesting that Adnab-9 is a premalignant marker in these lesions. Labeling of invasive IPMN's identified a group of patients with a superior overall survival (p = 0.027). Conclusion. Adnab-9 labeling-characteristics appear similar for both IPMNs and adenomatous polyps, suggesting that they are analogous lesions. Adnab-9 labeling may also be a useful prognostic marker for invasive intraductal papillary mucinous neoplasms.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 141-150 |
| Number of pages | 10 |
| Journal | International Journal of Pancreatology |
| Volume | 29 |
| Issue number | 3 |
| State | Published - 2001 |
Fingerprint
Keywords
- Colorectal cancer
- Immunostaining
- Intraductal papillary mucinous neoplasms
- Monoclonal antibody
- Pancreatic ductal cancer
- Severely dysplastic adenomatous colonic polyps
ASJC Scopus subject areas
- Gastroenterology
- Endocrinology
- Oncology
Cite this
Prognostic significance of the labeling of Adnab-9 in pancreatic intraductal papillary mucinous neoplasms. / Tobi, Martin; Hatfield, James; Adsay, Volkan; Galagan, Katherine; Kozarek, Richard; Inagaki, Mitsuhiro; Kasai, Shinichi; Tokusashi, Yoshihiko; Obara, Takeshi; Hruban, Ralph H; Lough, John; Barkun, Alan N.; Jabbari, Mansour; Sheikh, Rafiq; Ruebner, Boris; Lawson, Michael J.; Ben-Josef, Edgar; Fligiel, Suzanne.
In: International Journal of Pancreatology, Vol. 29, No. 3, 2001, p. 141-150.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Prognostic significance of the labeling of Adnab-9 in pancreatic intraductal papillary mucinous neoplasms
AU - Tobi, Martin
AU - Hatfield, James
AU - Adsay, Volkan
AU - Galagan, Katherine
AU - Kozarek, Richard
AU - Inagaki, Mitsuhiro
AU - Kasai, Shinichi
AU - Tokusashi, Yoshihiko
AU - Obara, Takeshi
AU - Hruban, Ralph H
AU - Lough, John
AU - Barkun, Alan N.
AU - Jabbari, Mansour
AU - Sheikh, Rafiq
AU - Ruebner, Boris
AU - Lawson, Michael J.
AU - Ben-Josef, Edgar
AU - Fligiel, Suzanne
PY - 2001
Y1 - 2001
N2 - Background. Pancreatic intraductal papillary mucinous neoplasms (IPMN), morphologically resembling colonic adenomas, often have an indefinable malignant potential. We used a monoclonal antibody (MAb) raised against colonic adenomas, Adnab-9, to identify patients with a better prognosis. Methods. We assessed Adnab-9-labeled sections of these neoplasms from 50 patients, 13 pancreatic adenocarcinomas, and 32 colonic adenomas using standard immunohistochemical techniques. Results. 26% of the IPMNs labeled with Adnab-9 as compared to 0% of pancreatic ductal cancers or surrounding benign tissues, (p <0.001) and 53% of adenomas (p <0.025). Labeling in IPMNs was usually seen in the noninvasive epithelium suggesting that Adnab-9 is a premalignant marker in these lesions. Labeling of invasive IPMN's identified a group of patients with a superior overall survival (p = 0.027). Conclusion. Adnab-9 labeling-characteristics appear similar for both IPMNs and adenomatous polyps, suggesting that they are analogous lesions. Adnab-9 labeling may also be a useful prognostic marker for invasive intraductal papillary mucinous neoplasms.
AB - Background. Pancreatic intraductal papillary mucinous neoplasms (IPMN), morphologically resembling colonic adenomas, often have an indefinable malignant potential. We used a monoclonal antibody (MAb) raised against colonic adenomas, Adnab-9, to identify patients with a better prognosis. Methods. We assessed Adnab-9-labeled sections of these neoplasms from 50 patients, 13 pancreatic adenocarcinomas, and 32 colonic adenomas using standard immunohistochemical techniques. Results. 26% of the IPMNs labeled with Adnab-9 as compared to 0% of pancreatic ductal cancers or surrounding benign tissues, (p <0.001) and 53% of adenomas (p <0.025). Labeling in IPMNs was usually seen in the noninvasive epithelium suggesting that Adnab-9 is a premalignant marker in these lesions. Labeling of invasive IPMN's identified a group of patients with a superior overall survival (p = 0.027). Conclusion. Adnab-9 labeling-characteristics appear similar for both IPMNs and adenomatous polyps, suggesting that they are analogous lesions. Adnab-9 labeling may also be a useful prognostic marker for invasive intraductal papillary mucinous neoplasms.
KW - Colorectal cancer
KW - Immunostaining
KW - Intraductal papillary mucinous neoplasms
KW - Monoclonal antibody
KW - Pancreatic ductal cancer
KW - Severely dysplastic adenomatous colonic polyps
UR - http://www.scopus.com/inward/record.url?scp=0035739657&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0035739657&partnerID=8YFLogxK
M3 - Article
C2 - 12067217
AN - SCOPUS:0035739657
VL - 29
SP - 141
EP - 150
JO - Journal of Gastrointestinal Cancer
JF - Journal of Gastrointestinal Cancer
SN - 1941-6628
IS - 3
ER -